Moderna, Inc.
MRNA
2 filings analyzed · latest FHS 54
Filings
| Filing | FHS | Band | Δ | Top highlight |
|---|---|---|---|---|
| 10-Q · 2026-07-31 | 54 | Caution | -3 | Net loss reached $2,125 million for the first six months of 2026, driven by high R&D expenses of $1,300 million and cost of sales of $1,048 million. |
| 10-Q · 2026-05-01 | 57 | Caution | first | Total revenue increased significantly to $389 million in Q1 2026 from $108 million in Q1 2025, driven by higher net product sales of COVID and RSV vaccines. |
Automated research summaries derived from SEC filings. Not investment advice.